Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time

NCT00513981 is registered in ClinicalTrials.gov with Children's Cancer and Leukaemia Group as lead sponsor.

NCT NCT00513981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00513981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time
Lead sponsor
Children's Cancer and Leukaemia Group
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2009
Enrollment
36 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, sarcoma, unspecified childhood solid tumor, protocol specific